TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05603884
Drug: Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: venetoclax combining chidamide and azacitidine (VCA) 28 days per cycle × 2 cycles； 1) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7 dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen 28 days per cycle ×2 cycles；~1）dicitabine 25mg d1-3，2）liposome mitoxantrone 20mg d4，3）cytarabine 10mg/m2 Q12h d1-7 4）G-CSF 300ug d-1 until WBC \> 20×109/L
Study: NCT04542733
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus will be given with tacrolimus.
Study: NCT04542733
Drug: reduced dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose tacrolimus will be given with or without leflunomide
Study: NCT05951049
Drug: AT02
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage Form: Solution for injection/infusion Dosage level: Different dose levels of AT02 Route of Administration: Intravenous use
Study: NCT06649539
Drug: Collagenase Clostridium Histolyticum
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 Series given to each participant, 6 weeks apart. Medication administered on back-to-back days. If failing to achieve an adequate response, men may receive up to 2 additional series 9-12 months after the 4th series.~Total of 0.9 mg administered with each series, diluted to 0.8 mL
Study: NCT06649539
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Men will be prescribed sildenafil 25 mg nightly beginning treatment day 2 until 6 weeks after final injection of the final series.
Study: NCT06649045
Drug: Orforglipron
Normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04815902
Drug: Fisetin
Normalized name: FISETIN
DrugBank: Fisetin (DB07795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Fisetin 20 mg/kg taken for 10 days total.
Study: NCT04815902
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5 mg oral Losartan taken for 30 days total.
Study: NCT04815902
Drug: Placebo - Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.
Study: NCT04815902
Drug: Placebo Fisetin
Normalized name: fisetin
DrugBank: Fisetin (DB07795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.
Study: NCT06192108
Drug: Orforglipron
Normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06192108
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT05141864
Drug: Lidocaine 2 % Topical Cream
Normalized name: lidocaine 2 % Topical Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control group will use lidocaine 2% gel during the digital rectal examination.
Study: NCT05181462
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8/15, in cycles of 3-4 weeks
Study: NCT05181462
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2 IV on days 1 and 8/15, in cycles of 3-4 weeks
Study: NCT05181462
Drug: Nadunolimab
Normalized name: Nadunolimab
DrugBank: Nadunolimab (DB18249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadunolimab escalation (DL -1: 0.5 mg/Kg, DL 1: 1 mg/kg, DL 2: 2.5 mg/kg), DL 3: 5 mg/kg IV on days 1 and 8/15, in cycles of 3-4 weeks.
Study: NCT05075577
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily oral dose of enzalutamide
Study: NCT05075577
Drug: EPI-7386 with Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily oral dose of EPI-7386 in combination of enzalutamide
Study: NCT05995054
Drug: Obinutuzumab Injection [Gazyva]
Normalized name: obinutuzumab Injection [Gazyva]
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 110 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment.
Study: NCT06575153
Drug: ART5803
Normalized name: ART5803
DrugBank: ART5803 (DB18379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
Study: NCT06306638
Drug: Verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT06575738
Drug: Injectable semaglutide
Normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous weekly injectable semaglutide
Study: NCT06561438
Drug: Vortioxetine 20Mg Tab
Normalized name: VORTIOXETINE 20MG TAB
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg oral vortioxetine tablet 2 hours before the procedure
Study: NCT05007873
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05318976
Drug: XPro1595
Normalized name: XPro1595
DrugBank: XPro1595 (DB16454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XPro1595 will be delivered by subcutaneous injection once a week
Study: NCT04811027
Drug: eftilagimod alpha
Normalized name: alpha tocopherol
DrugBank: Eftilagimod alfa (DB16150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APC activator, MHC II agonist, LAG-3 fusion protein
Study: NCT04811027
Drug: pembrolizumab (KEYTRUDA®)
Normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-PD-1 antibody
Study: NCT06432309
Drug: Opicapone 50 mg
Normalized name: opicapone 50 MG
DrugBank: Opicapone (DB11632)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evaluate the addition of the COMT-I, Opicapone, to the Levodopa-Carbidopa intestinal gel in Parkinson's Disease patients with motor fluctuations.
Study: NCT06432309
Drug: Duodopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evaluate Levodopa-Carbidopa intestinal gel in Parkinson's Disease patients with motor fluctuations.
Study: NCT06572631
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06572631
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00002260
Drug: Alovudine
Normalized name: Alovudine
DrugBank: Alovudine (DB06198)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06574048
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg IV Dexamethasone
Study: NCT06134375
Drug: Tetrathiomolybdate
Normalized name: Tetrathiomolybdate
DrugBank: Tetrathiomolybdate (DB05088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrathiomolybdate (TM): Ammonium tetrathiomolybdate (TM), an oral copper lowering agent, has been established as safe in patients with Wilson's disease and advanced cancer. TM forms stable copper-molybdenum clusters sequestering copper and thereby limiting its availability, for the proper functioning of angiogenic factors, including secreted metalloenzymes. TM inhibits several copper containing enzymes including ceruloplasmin, cytochrome oxidase, tyrosinase and downregulates cytokines such as MMP9 and VEGF as well as transcription factors such as NF-kB. Both pre-clinical and clinical data suggest that TM may effectively reduce both overt and sub-clinical tumor load by both targeting the metastases initiating stem cell component of primary tumors inactivating Complex IV, shifting oxphos to glycolysis and through stromal remodeling.
Study: NCT06134375
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: If pembrolizumab was administered in the neoadjuvant setting and the oncology team chooses to continue in the adjuvant setting, standard doses will be used (200 mg IV Q3weeks or 400 mg IV Q6 weeks for one year total as per package insert)
Study: NCT06299319
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered twice during the trial, in conjunction with supportive therapy.
Study: NCT05436093
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All study participants will undergo one 18F-FDG PET/CT scan.
Study: NCT04599634
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously, on Days 1, 2, 8 and 15 of Cycle 1 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg for dose finding phase. For expansion phase, administered on Days 1, 2, 8 and 15 of Cycle 2 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg.
Study: NCT04599634
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For follicular lymphoma (FL) patients in dose finding phase, administered orally at a dose of 600mg or 800mg depending on tolerance, daily, cycles 1-12. For MZL (Marginal Zone Lymphoma), MCL (Mantle Cell Lymphoma) or CLL (Chronic Lymphocytic Leukemia) patients in dose finding phase administered at an escalating dose from 20mg-400mg Cycle 1 on days 1-35, and at a dose of 400mg per day for Cycles 2-12. Patients in expansion phase will receive target dose established from dose finding cohorts daily for all 12 cycles.
Study: NCT04599634
Drug: Magrolimab
Normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously, starting at 1 mg/kg on second day of first cycle then 30mg/kg on days 8, 15 and 22 of cycle 1 and days 1 and 15 of cycles 2-12 for patients in both the dose finding and expansion phases.
Study: NCT04599634
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premedication with 25-50mg diphenhydramine 30-60 minutes prior to obinutuzumab doses.
Study: NCT04599634
Drug: Prednisone/prednisolone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premedication with 100mg intravenous prednisone/prednisolone 30-60 minutes before obinutuzumab infusion.
Study: NCT04599634
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premedication with intravenous methylprednisolone 80mg 30-60 minutes before obinutuzumab infusion.
Study: NCT05629585
Drug: Dato-DXd
Normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental drug. Provided in 100mg vials. IV infusion
Study: NCT06547944
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160mg bid/d, from C1 to CR and MRD-negative or C24
Study: NCT06547944
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: From C3 dose escalation, all 3 dose groups climbed from 5 mg/d to 10 mg/d, 15 mg/d, and 20 mg/d respectively, Taking 21 days of medication and 7 days of rest, 1 cycle every 28 days to CR and MRD-negative or C24
Study: NCT06547944
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000 mg C1, d1/d8/15; 1000 mg C2-6, d1
Study: NCT05629585
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Experimental drug. Provided in 50mg vials. IV infusion
Study: NCT05629585
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Active Comparator. Provided in 100mg vials. IV infusion
Study: NCT06795178
Drug: FP-014
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Albutrepenonacog alfa (DB13884)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 11.25 mg in a prefilled, ready-to-use, long-acting formulation
Study: NCT05650879
Drug: Fam-Trastuzumab Deruxtecan-Nxki
Normalized name: fam-trastuzumab deruxtecan-nxki
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous
Study: NCT05650879
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous
Study: NCT06199297
Drug: Atezolizumab combined with Bevacizumab
Normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Atezolizumab 1200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
Study: NCT06199297
Drug: Sintilimab combined with Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sintilimab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
Study: NCT05987072
Drug: Sisunatovir
Normalized name: Sisunatovir
DrugBank: Sisunatovir (DB15674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state
Study: NCT06249555
Drug: Vedolizumab (VDZ)
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive VDZ as part of routine care.
Study: NCT06249555
Drug: Ustekinumab (UST)
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive UST as part of routine care.
Study: NCT06249555
Drug: Risankizumab (RISA)
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive RISA as part of routine care.
Study: NCT06233981
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One week before or during the radiotherapy, patients receive concurrent Tislelizumab at a dose of 200mg. Subsequently, Tislelizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Tislelizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
Study: NCT05670236
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mL of 1% lidocaine hydrochloride for each intraarticular knee injection
Study: NCT01006096
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg tablet, once daily for 16 weeks
Study: NCT05842941
Drug: DNL343
Normalized name: DNL343
DrugBank: DNL343 (DB18678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNL343 is administered orally once daily per day for 24 weeks.
Study: NCT05724108
Drug: Lutetium Lu 177 Dotatate
Normalized name: Lutetium Lu 177 dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05724108
Drug: Triapine
Normalized name: Triapine
DrugBank: Triapine (DB11940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06213233
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participant will take Epidiolex days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).
Study: NCT05558982
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg intravenous (IV) on day 1 every 21 days.
Study: NCT05017025
Drug: Aurora A Kinase Inhibitor LY3295668
Normalized name: Aurora a kinase inhibitor ly3295668
DrugBank: Erbumine (DB18019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05017025
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06144606
Drug: Tecartus
Normalized name: Tecartus
DrugBank: Brexucabtagene autoleucel (DB15699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecartus is a CD19 directed CAR T-cell therapy that utilizes CD28 costimulatory and CD3 zeta stimulatory domains. Tecartus is manufactured from purified autologous T-cells via retroviral transduction with a median time to product release of 13 days.
Study: NCT05933499
Drug: IV bimagrumab
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bimagrumab (30mg/kg IV administered at 0, 4, 16, 28, and 40 weeks)
Study: NCT05678933
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.
Study: NCT05678933
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.
Study: NCT05678933
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
Study: NCT05678933
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.
Study: NCT05678933
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
Study: NCT05933499
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide 2.4mg SQ qweek
Study: NCT00045877
Drug: Recombinant Human Interleukin-2 and Rituximab
Normalized name: Recombinant human interleukin-2
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06350630
Drug: Hydroxychloroquine Oral Tablet
Normalized name: hydroxychloroquine Oral Tablet
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active hydroxychloroquine once daily by oral route at 6.5 mg/kg of ideal weight/day, with maximal dose of 400mg/day for 3 years
Study: NCT05223088
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 3-6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
Study: NCT05223088
Drug: Apatinib Mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive apatinib, 250mg, qd，every 3 weeks for 2-5 weeks.
Study: NCT05223088
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 3-6 weeks.
Study: NCT05223088
Drug: Tegafur
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Participants will receive Tegafur, day 1-14 of every 3 weeks for 3-6 weeks.
Study: NCT04571619
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be encouraged to switch from their current full agonist opioid medication to the partial opioid agonist, buprenorphine. Participants who switch to Buprenorphine will be provided with individualized buprenorphine treatment recommendations. Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors. Participants who do not meet the Phase 2 eligibility criteria will not be offered buprenorphine. All participants will continue to be followed from Week 24 until Week 36 for ascertainment of pain, opioid use, and other outcomes to address durability of the effects of PCST, and, for those who switch to buprenorphine, to assess buprenorphine acceptability, tolerability, and efficacy as exploratory outcomes.